- body {font-family: 'Verdana';}

Main menu


New Drug For The Treatment Of Psoriasis Plaque : FDA Approved Drugs and Others

Psoriasis currently has no cure. Dermatologists offer treatments that can assist their patients in achieving clear or near-clear skin with less systemic inflammation. 

Researchers focus on new, more effective new treatments, especially for patients with moderate to severe psoriasis.

Psoriasis is the result of a reaction between skin cells and the immune system (TNF-alpha or T cells and interleukins). Inflammations cause psoriasis. It is known to be an inflammatory disease.


The Old Psoriasis Treatment

For many years, a variety of treatments (systemic and topical) were available to treat psoriasis patients. Salicylic acid application, emollients, corticosteroids, calcitriol, ultraviolet light, methotrexate, anthralin, acitretin, coal tar, and dithranol were all used and prescribed as a first treatment for the disease. 

New Drugs for Chronic Plaque Psoriasis: Biologics

Biologics target specific proteins of the immune system and are given by injection. The biologic drugs below have been approved by the FDA for treatments for psoriasis.

TNF-alpha Cimzia (certolizumab pegol): Enbrel (etanercept), Humira (adalimumab), Remicade (infliximab), Simponi (golimumab) and Simponi Aria (golimumab)

IL-12, IL-23 Inhibitors: Stelara (ustekinumab)

IL-17 Inhibitors: Cosentyx (secukinumab), Siliq (brodalumab) and Taltz (ixekizumab), Abatacept (Orencia)

IL-23 Inhibitors: Ilumya (tildrakizumab-asmn), Skyrizi (risankizumab-rzaa), and Tremfya (guselkumab)

Psoriasis can be effectively treated with biologics: psoriasis activity is reduced by at least 75% in many people in clinical trials. The choice of drug depends on the type of patient. 

However, there are some disadvantages. Biologics can be quite costly. They're generally safe, but they can increase the risk of infection and cancer. To ensure that you stay healthy, your doctor will need to keep a careful eye on you.

The newest psoriasis drugs

New Topical Medication 

Tapinarof (Vtama) cream 1% is a new topical steroid-free aryl hydrocarbon receptor agonist topical cream. It may be used to treat sensitive regions of the body and is approved to treat moderate to severe plaque psoriasis in adults. The Food and Drug Administration has approved it for this type of psoriasis. It is applied once per day. Vtama from Dermavant has been approved by the Food and Drug Administration.

This new drug application has been shown to be successful in causing remission and is safe to use for an extended period of time. 

Other New Treatments

Apremilast (Otezla)

Apremilast is a new treatment for psoriasis and psoriatic arthritis in adults. It inhibits phosphodiesterase-4, which regulates inflammation. Trials have demonstrated that apremilast reduces the severity of moderate to severe chronic plaque psoriasis. Otezla is the first pill approved by the FDA to treat all severities of psoriasis plaques—mild, moderate, and severe.


Interleukin-23 antagonists, Skyrizi, Ilumya, and Tremfya

They are the most recent medications approved by the FDA.


It is the first selective allosteric tyrosine kinase 2 inhibitor. Recently, Bristol Myers Squibb published new Two-Year Deucravacitinib Data showing the Durable Efficacy and Consistent Safety Profile in the Treatment of Severe and Moderate Plaque Psoriasis.


Systemic therapies are reserved for cases that have failed topical treatments and phototherapy. If you take the medication, you should visit your doctor regularly.


You Will Read